by RNA | Oct 20, 2016 | Client Success
THE PROBLEM: Novel technology platform could be used across a wide range of rare diseases, so executive team and board want an independent, evidence-based view of commercial opportunity to complement the scientific analysis. THE SOLUTION: Interviews with KOL... Read More
